Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | CEL | P19835 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12375908 | 0.90 | CYP1A2 (0.34) | SIRT2 | |
| SCHEMBL12375919 | 0.90 | SIRT2 (0.36) | SIRT2 | |
| SCHEMBL13668190 | 0.89 | MAOA (0.34) | SIRT2 | |
| SCHEMBL12376089 | 0.85 | SIRT2 (0.33) | SIRT2 | |
| SCHEMBL12375905 | 0.85 | MAOA (0.41) | HTR2AHTR2CCEL | |
| SCHEMBL12376030 | 0.85 | MAOB (0.31) | HTR2AHTR2C | |
| SCHEMBL12375907 | 0.85 | MAOA (0.36) | CEL | |
| SCHEMBL12375918 | 0.84 | MAOA (0.36) | SIRT2 | |
| SCHEMBL12375991 | 0.83 | MAOA (0.33) | SIRT2 | |
| SCHEMBL12375921 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
| US-7951305-B2 | Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | HCN2, PIEZO1, TRPV4 | SIRT2 4255/4885HTR2A 1968/4885HTR2C 688/4885 |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, HCN2, HCN1 | SIRT2 4609/4885HTR2A 894/4885HTR2C 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.